Drug Trial Radar · NCT06194825
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Actual
Start
Dec 1, 2023
Primary completion
May 13, 2026
Study completion Jan 5, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in Chinese participants with hereditary or wild-type transthyretin amyloid cardiomyopathy.
Conditions
- Transthyretin Amyloid Cardiomyopathy
Interventions
EplontersenDrug
Eplontersen by subcutaneous injection
PlaceboDrug
Eplontersen-matching placebo by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change of serum TTR concentration from baselineTime frame: up to 24 weeks
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Ha’erbin, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Jinan, China
Research Site
Nanchang, China
Research Site
Shanghai, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.